[go: up one dir, main page]

MX9702037A - Metodo para minimizar el efecto uterotrofico de tamoxifeno y analogos de tamoxifeno. - Google Patents

Metodo para minimizar el efecto uterotrofico de tamoxifeno y analogos de tamoxifeno.

Info

Publication number
MX9702037A
MX9702037A MX9702037A MX9702037A MX9702037A MX 9702037 A MX9702037 A MX 9702037A MX 9702037 A MX9702037 A MX 9702037A MX 9702037 A MX9702037 A MX 9702037A MX 9702037 A MX9702037 A MX 9702037A
Authority
MX
Mexico
Prior art keywords
tamoxifeno
analogs
minimize
uterotrophic effect
compounds
Prior art date
Application number
MX9702037A
Other languages
English (en)
Inventor
Henry Uhlman Bryant
Steven Anthony Fontana
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MX9702037A publication Critical patent/MX9702037A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente invencion proporciona un miembro para minimizar efecto uterotrofico de compuestos antiestrogénicos de trifenilmetileno no esteroides, cuando tales compuestos se administran para el tratamiento o prevencion de carcinoma de mama, vía la coadministracion de ciertos compuestos naftilo antiestrogénicos. También se proporcionan composiciones farmacéuticas.
MX9702037A 1994-09-20 1995-09-18 Metodo para minimizar el efecto uterotrofico de tamoxifeno y analogos de tamoxifeno. MX9702037A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/308,904 US5554628A (en) 1994-09-20 1994-09-20 Method for minimizing the uterothrophic effect of tamoxifen and tamoxifen analogs
PCT/US1995/012345 WO1996009051A1 (en) 1994-09-20 1995-09-18 A method for minimizing the uterotrophic effect of tamoxifen and tamoxifen analogs

Publications (1)

Publication Number Publication Date
MX9702037A true MX9702037A (es) 1997-06-28

Family

ID=23195869

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9702037A MX9702037A (es) 1994-09-20 1995-09-18 Metodo para minimizar el efecto uterotrofico de tamoxifeno y analogos de tamoxifeno.

Country Status (16)

Country Link
US (1) US5554628A (es)
EP (1) EP0702961B1 (es)
JP (1) JPH10506111A (es)
KR (1) KR970705999A (es)
AT (1) ATE220919T1 (es)
AU (1) AU692932B2 (es)
CA (1) CA2200205A1 (es)
CZ (1) CZ82097A3 (es)
DE (1) DE69527480D1 (es)
FI (1) FI971155A0 (es)
HU (1) HUT77954A (es)
MX (1) MX9702037A (es)
NO (1) NO971229L (es)
NZ (1) NZ294176A (es)
RU (1) RU2158589C2 (es)
WO (1) WO1996009051A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5811421A (en) * 1995-07-31 1998-09-22 Eli Lilly And Company Naphthyl and dihydronaphthyl intermediates, compounds, compositions, and methods
DE69830218T2 (de) * 1997-08-07 2006-02-02 Eli Lilly And Co., Indianapolis 1-[4-Substituierte Alkoxy)benzylnaphthalinderivate als Östrogeninhibitoren
EP1113007A1 (en) 1999-12-24 2001-07-04 Pfizer Inc. Tetrahydroisoquinoline compounds as estrogen agonists/antagonists
AR030064A1 (es) * 2000-07-06 2003-08-13 Wyeth Corp Metodos para inhibir los efectos uterotroficos de los agentes estrogenicos
DE602005017577D1 (de) * 2004-01-22 2009-12-24 Lilly Co Eli Selektive östrogen-rezeptor-modulatoren
WO2012091425A2 (ko) * 2010-12-27 2012-07-05 전남대학교산학협력단 4-하이드록시 타목시펜 유사체 또는 이의 약학적으로 허용가능한 염을 유효성분으로 포함하는, 대사증후군 관련 질환의 예방 또는 치료용 조성물
KR101311534B1 (ko) * 2010-12-27 2013-09-25 전남대학교산학협력단 4-하이드록시 타목시펜 유사체 또는 이의 약학적으로 허용가능한 염을 유효성분으로 포함하는 당뇨병 치료 또는 예방용 조성물
WO2012119010A2 (en) * 2011-03-01 2012-09-07 Indiana University Research And Technology Corporation Materials for inhibiting aromatase and method of using the same to diagnose, treat and monitor breast cancer
CN104203961B (zh) * 2012-03-05 2017-05-17 泽维尔大学 作为用于治疗乳腺癌的基于硼的4‑羟基他莫昔芬和因多昔芬前药
CZ305571B6 (cs) * 2014-01-29 2015-12-16 Smart Brain s.r.o. Deriváty tamoxifenu k léčbě neoplastických chorob, zejména s vyšší hladinou proteinu HER2

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4133814A (en) * 1975-10-28 1979-01-09 Eli Lilly And Company 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents
US4230862A (en) * 1975-10-28 1980-10-28 Eli Lilly And Company Antifertility compounds
DE2860900D1 (en) * 1977-08-22 1981-11-05 Ici Plc Triphenylalkene derivatives, process for their preparation and pharmaceutical compositions containing them
US4418068A (en) * 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
US4380635A (en) * 1981-04-03 1983-04-19 Eli Lilly And Company Synthesis of acylated benzothiophenes
NZ200204A (en) * 1981-04-03 1985-05-31 Lilly Co Eli Benzothiophene derivatives and process for preparation
DE3121175A1 (de) * 1981-05-27 1982-12-16 Klinge Pharma GmbH, 8000 München Erythro-1,2,3-triphenyl-1-pentanon-derivate sowie verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
US4656187A (en) * 1981-08-03 1987-04-07 Eli Lilly And Company Treatment of mammary cancer
US5147880A (en) * 1991-07-22 1992-09-15 Eli Lilly And Company Benzo[a]fluorene compounds
TW366342B (en) * 1992-07-28 1999-08-11 Lilly Co Eli The use of 2-phenyl-3-aroylbenzothiophenes in inhibiting bone loss
DE4329344A1 (de) * 1993-08-27 1995-03-02 Schering Ag Progesteronantagonistisch- und antiöstrogen wirksame Verbindungen für die Behandlung des Leiomyomata uteri
US5604248A (en) * 1994-05-05 1997-02-18 Eli Lilly And Company Method for minimizing the uterotrophic effect of tamoxifen and tamoxifen analogs

Also Published As

Publication number Publication date
CA2200205A1 (en) 1996-03-28
NO971229D0 (no) 1997-03-17
JPH10506111A (ja) 1998-06-16
US5554628A (en) 1996-09-10
EP0702961B1 (en) 2002-07-24
FI971155L (fi) 1997-03-19
AU692932B2 (en) 1998-06-18
FI971155A7 (fi) 1997-03-19
AU3686295A (en) 1996-04-09
ATE220919T1 (de) 2002-08-15
NZ294176A (en) 1999-10-28
WO1996009051A1 (en) 1996-03-28
NO971229L (no) 1997-03-17
DE69527480D1 (de) 2002-08-29
HUT77954A (hu) 1998-12-28
EP0702961A3 (en) 1999-11-10
EP0702961A2 (en) 1996-03-27
FI971155A0 (fi) 1997-03-19
RU2158589C2 (ru) 2000-11-10
CZ82097A3 (en) 1997-08-13
KR970705999A (ko) 1997-11-03

Similar Documents

Publication Publication Date Title
AR020019A1 (es) Composicion farmaceutica para la prevencion o el tratamiento de cancer de mama
BR0115109A (pt) Agentes terapêuticos e métodos de uso dos mesmos para a modulação da angiogênese
MX9204140A (es) Nuevos derivados de analogos de taxol, procedimiento para su preparacion y composicion farmaceutica que los contienen.
UY26130A1 (es) Compuestos para tratar la obesidad
HUS1300063I1 (hu) Egy ingenán vegyület alkalmazása rák kezelésére alkalmas gyógyszerkészítmény elõállítására
KR980000447A (ko) 미르타자핀과 하나 이상의 선택적인 세로토닌 재이용 저해제로 이루어진 약학 조성물
BR9814343A (pt) Composições e processos para proteção da pele a partir de imunoextição induzida por uv e danos à pele
ECSP003682A (es) Compuestos para el tratamiento de la isquemia
AR035158A1 (es) Inhibidores de recaptacion de norepinefrina altamente selectivos y metodo para usar los mismos
NO20053104D0 (no) Oral, analgesisk doseringsform med forlenget frigivelse for administrering ±n gang pr. dag.
EA200100154A1 (ru) Бензоциклогептены, способ их получения, содержащие их фармацевтические препараты и их применение для получения лекарственных средств
MX9702037A (es) Metodo para minimizar el efecto uterotrofico de tamoxifeno y analogos de tamoxifeno.
KR950031060A (ko) 골다공증 치료용 약제학적 조성물
BR0114759A (pt) Utilização de inibidores da apoptose dos perìcitomas para o tratamento e/ou a prevenção da retinopatia diabética
ECSP930933A (es) Composicion farmaceutica y procedimiento para prepararla
CO5070569A1 (es) Compuesto de aminoazol o una sal farmaceuticamente aceptable del mismo y medicamento que los contienen
AR043071A1 (es) Uso de macrolidos para el tratamiento del cancer y degeneracion macular y una composicion farmaceutica
RU94044356A (ru) Применение 2-фенил-3-ароилбензотиофенов для увеличения экспрессии тромбомодулина для ингибирования тромботического расстройства, для увеличения активации протеина с
MX163574B (es) Procedimiento para preparar una composicion farmaceutica para inhalacion conteniendo un gangliosido
SE8904354D0 (sv) A pharmaceutical composition
ES2123499T3 (es) Metodos y composiciones para tratamiento de infecciones virales.
MX16046A (es) Procedimiento para la preparacion de 2-amino-1,2,3,4-tetrahidronaftalenos substituidos en el anillo,compuesto obtenido y composicion farmaceutica que lo incluye
NO983177L (no) Anvendelse av 1-enantiomeren av centkroman til fremstilling av et farmasaytisk preparat for behandling eller profylakse av brystkreft
BR0111051A (pt) Produto farmacêutico e dose farmacêutica diária para administração a um paciente, regime de dose prover um efeito anti-androgênico e um efeito anti-estrogênico em um paciente, uso de um composto e de tamoxifeno ou de um sal ou solvato farmaceuticamente aceitável destes, e, método para prover um efeito anti-androgênico em um paciente
CO5060499A1 (es) Metodos y composiciones para el tratamiento de enfermedad de reflujo gastroesofagico